ArticleBiologics : targets & therapy2025

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study.

Silvana Ancona et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.